Pavmed Stock Earnings Reports

PAVmed completed a multi-year recapitalization that has simplified its capitalization to common stock and term debt, which management says positions the company to operate as a high-growth, diversified life sciences platform with independently financed subsidiaries under a shared-services model. The company has relaunched its medical device portfolio under a newly appointed device executive (Joe Virgilio) to actively advance assets such as PortIO and an endoscopic imaging technology (Octeris). PAVmed remains the largest shareholder of Lucid Diagnostics (~15% common; ~25% voting influence) and highlighted Lucid’s nearing key milestones including anticipated Medicare coverage, VA orders via a federal supply schedule, positive commercial payer engagement, and a recent capital raise that extends Lucid’s runway into 2027. Veris is in commercial rollout with Ohio State University (OSU), with EHR integration live, positive feedback, and a target registry of 1,000 patients in the first year; development of an implantable physiologic monitor is progressing toward a planned FDA submission by year-end with a new CDMO partner (Valentium) and focus on achieving a two-year battery life. Financially, PAVmed reported $6.5 million cash at March 31 (excluding potential future receipts tied to warrant exercises), a GAAP net loss before preferred dividends of $1.1 million for the quarter and net loss attributable to PAVmed of $60,000 (prior to ~$6.9 million in preferred dividends). The company issued warrants (totaling $30 million in exercise value) that are callable upon publication of a positive EsoGuard LCD and noted that near-term operating expense increases will mainly reflect R&D for the Veris implantable device.